Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3055% below fair value
$1.08−0.02 (-1.82%)
Close on Nov 20, 2026Market cap $4.97MP/E –Yield –
Biomerica free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Biomerica's free cash flow for the twelve months ending May 31, 2024 was -$5.41M. For fiscal 2024 it was -$5.41M. The highest annual figure on record is $1.14M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | May 31, 2024 | -$5.41M | – |
| FY2023 | May 31, 2023 | -$5.54M | – |
| FY2022 | May 31, 2022 | -$536.00K | – |
| FY2021 | May 31, 2021 | -$5.39M | – |
| FY2020 | May 31, 2020 | -$4.33M | – |
| FY2019 | May 31, 2019 | -$2.35M | – |
| FY2018 | May 31, 2018 | -$1.30M | – |
| FY2017 | May 31, 2017 | -$818.94K | – |
| FY2016 | May 31, 2016 | -$300.34K | – |
| FY2015 | May 31, 2015 | -$415.98K | – |
| FY2014 | May 31, 2014 | -$999.51K | -187.9% |
| FY2013 | May 31, 2013 | $1.14M | – |
| FY2012 | May 31, 2012 | -$17.39K | -109.3% |
| FY2011 | May 31, 2011 | $187.72K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$1.07M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$1.80M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$848.00K | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$1.70M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$963.00K | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.73M | -173.8% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$1.24M | -193.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$1.61M | -2373.1% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$4.28M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $2.34M | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $1.33M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $70.70K | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.04M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$1.41M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.31M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.64M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$3.50M | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$458.32K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$361.99K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$10.33K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$1.01M | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$276.51K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$259.41K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$794.74K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$378.09K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$510.20K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$271.59K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$144.69K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$333.73K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$151.64K | – |
See a number that looks wrong?